Scholarlink

Purpose and Scope of Review <p>We discuss updates in the weight gain risk stratification of various atypical antipsychotics, dose-dependency effects, the role of the gut microbiome in the mechanism of AWIG, and the potential of GLP-1 receptor agonists and antipsychotic switching in managing and mitigating the adverse effect of weight gain. These updates are organized into 3 sections: Prediction, Mechanism, and Treatment.</p> Recent Findings <p>Different atypical antipsychotics are associated with different risk profiles for weight gain, and switching from higher to lower risk antipsychotics is a promising direction for mitigating this adverse effect. Other treatments that target weight gain in general, such as lifestyle modifications and GLP-1 agonists, are also effective in managing AWIG. The dose-dependent effect of atypical antipsychotics on weight varies by patient characteristics such as age and sex as well as medication factors such as duration of treatment. These differences require further study pry. Recent insights on the mechanism of AWIG highlight the importance of alterations in the gut microbiome, neurotransmitter-receptor interactions, appetite-regulating neuropeptides and hormones, and cell-signaling molecules such as adipokines and cytokines.</p> Summary <p>This review provides insight into the mechanisms by which atypical antipsychotics contribute to weight gain, the risk factors that predict the degree of AIWG, and potential treatments to manage weight gain in patients receiving therapeutic benefit from atypical antipsychotics.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Antipsychotic-Induced Weight Gain: What Have We Learned?

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年3月10日

查看全文
  • Akshatha Silas,
  • Margaret Musso,
  • Trygve Dolber

摘要

Purpose and Scope of Review

We discuss updates in the weight gain risk stratification of various atypical antipsychotics, dose-dependency effects, the role of the gut microbiome in the mechanism of AWIG, and the potential of GLP-1 receptor agonists and antipsychotic switching in managing and mitigating the adverse effect of weight gain. These updates are organized into 3 sections: Prediction, Mechanism, and Treatment.

Recent Findings

Different atypical antipsychotics are associated with different risk profiles for weight gain, and switching from higher to lower risk antipsychotics is a promising direction for mitigating this adverse effect. Other treatments that target weight gain in general, such as lifestyle modifications and GLP-1 agonists, are also effective in managing AWIG. The dose-dependent effect of atypical antipsychotics on weight varies by patient characteristics such as age and sex as well as medication factors such as duration of treatment. These differences require further study pry. Recent insights on the mechanism of AWIG highlight the importance of alterations in the gut microbiome, neurotransmitter-receptor interactions, appetite-regulating neuropeptides and hormones, and cell-signaling molecules such as adipokines and cytokines.

Summary

This review provides insight into the mechanisms by which atypical antipsychotics contribute to weight gain, the risk factors that predict the degree of AIWG, and potential treatments to manage weight gain in patients receiving therapeutic benefit from atypical antipsychotics.